DRIO
DarioHealth Corp.12.05
+0.05+0.42%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Comfort with consensus, breakeven quantified
Q&A largely reaffirmed prepared remarks on pipeline ramps and cost cuts, but management voiced comfort with analyst consensus for 2026 revenue growth—planning to exceed it slightly with H2 acceleration. They quantified cash flow breakeven at $38 million to $42 million in revenue, 80% driven by top-line expansion amid AI-fueled OpEx efficiencies narrowing non-GAAP losses 30%. Pipeline hit $122 million by folding in 2027 deals, up from last quarter's 2026-only view. Channel activations like HCSC demand preparatory investments, yet stay modest. Breakeven path hinges on growth. Confident tone persists; investors track enrollment in big Blues plans.
Key Stats
Market Cap
81.56MP/E (TTM)
-Basic EPS (TTM)
-10.87Dividend Yield
0%Recent Filings
8-K
Board gains bylaw powers
DarioHealth Corp. filed an Amended and Restated Certificate of Incorporation on February 2, 2026, after stockholder approval at the January 29 annual meeting. The key change empowers the board to alter or repeal bylaws, while stockholders retain that power too. Governance streamlined. No other impacts disclosed.
8-K
Shareholders approve directors, ratifications
DarioHealth shareholders overwhelmingly elected seven directors—including Hila Karah and Erez Raphael—to serve until the next annual meeting on January 29, 2026. They ratified auditors Kesselman & Kesselman, approved Nasdaq-compliant ratifications for prior preferred conversions and Twill acquisition shares, boosted the equity plan by 500,000 shares, and endorsed executive pay plus a charter tweak granting board bylaw powers. All passed handily.
10-Q
Q3 FY2025 results
DarioHealth's Q3 revenues fell 32.5% y/y to $5.0M (derived), yet gross margins expanded to 60.2% from 52.2% on lower amortization and hosting costs; operating loss narrowed to $9.5M from $12.0M as R&D and sales expenses dropped 39% and 32% y/y (derived). Cash swelled to $31.9M, bolstered by $17.4M equity raise and $32.5M Callodine term loan (SOFR+7.75%, matures April 2030), while repaying prior debt; ops cash burn eased to $20.1M YTD. Twill acquisition (closed Feb 2024) added $57.4M goodwill, $16.4M intangibles. Covenant waiver secured via equity cure. Stock volatility persists.
8-K
Credit amendment eases covenants
DarioHealth amended its Callodine credit agreement on November 5, 2025, resetting covenants, waiving Q2-Q3 2025 tests, and swapping minimum cash for $10M unencumbered liquid assets. Warrants reset to $15.3495 exercise price; $2.5M extra funding stays uncommitted. Lenders upped exit fee $150K; Dario paid $150K amendment fee. Cash flow reporting kicks in below $11M liquidity.
8-K
Dario raises $17.5M, eyes sale
DarioHealth closed a $17.5M private placement on September 23, 2025, selling 1,154,420 common shares and pre-funded warrants for 1,558,760 shares at $6.45 each to accredited investors. It accelerated Series C-1 preferred stock conversion effective September 25. Board launched strategic review after inquiries, hiring Perella Weinberg. Cash bolsters runway amid sale talks.
IPO
Website
Employees
Sector
Industry
BRGX
BioRegenx, Inc
0.02+0.00
DH
Definitive Healthcare Corp.
2.29-0.01
DOCS
Doximity, Inc.
43.80-0.85
FOXO
FOXO Technologies Inc.
0.00+0.00
HYDTF
Hydreight Technologies Inc
3.10-0.06
LFMD
LifeMD, Inc.
3.42+0.15
OMDA
Omada Health, Inc.
14.61+0.02
TALK
Talkspace, Inc.
3.55+0.04
TDOC
Teladoc Health, Inc.
7.41+0.07
VYND
VYNLEADS INC
0.32+0.00